In this exclusive interview, Dr Sabine Tejpar (University Hospital Leuven, Belgium) discusses the use of RAS testing in colon cancer and the FIRE-3 trial to uncover the intrinsic biological subtypes of the disease.
After a training in Internal medicine and Gastroenterology and a PhD in the programme of Molecular Oncology at the Centre for Human Genetics, UZ Leuven, in September 2003 Sabine Tejpar, MD, PhD, became an Associate Professor in the Department of Gastroenterology, Digestive Oncology Unit, UZ Leuven, Belgium. She works as a part-time clinician, part-time researcher (Senior Clinical Investigator of the Fund for Scientific Research- Flanders, Belgium), with a focus on basic and translational research in colorectal cancer. Her main research projects involve prognostic markers in adjuvant colorectal cancer and predictive markers for efficacy of EGFR inhibition.
Financial & competing interests disclosure
Sabine Tejpar serves on the speakers bureau for Merck Serono. The author has no other relevant affiliations or financial involvement with any organization or entity with a financial interest in or financial conflict with the subject matter or materials discussed in this work. This includes employment, consultancies, honoraria, stock ownership or options, expert testimony, grants or patents received or pending, or royalties.